New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 15, 2014
13:35 EDTLXRXLexicon study shows LX4211 lessens postprandial glucose levels
Lexicon Pharmaceuticals presented data at the 74th Scientific Sessions of the American Diabetes Association, ADA, in San Francisco on LX4211, an oral, first-in-class, dual inhibitor of sodium glucose transporters 1 and 2, SGLT1 and SGLT2, that is designed to lower blood glucose levels through two insulin-independent mechanisms of action. Results presented from a clinical study showed that LX4211 significantly reduced postprandial glucose levels in type 2 diabetes patients with moderate to severe renal impairment.
News For LXRX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
April 29, 2015
16:08 EDTLXRXLexicon announces 1-for-7 reverse stock split
Lexicon Pharmaceuticals announced that it will effect a reverse stock split at a ratio of one share of newly issued common stock for each seven shares of issued and outstanding common stock. Lexicon anticipates that the reverse stock split will be effective at 5:00 p.m. Eastern Time on May 20, 2015, and that its common stock will commence trading on a split-adjusted basis as of the opening of trading on May 21. Lexicon stockholders previously approved an amendment to Lexicon's certificate of incorporation to effect the reverse stock split at the discretion of Lexicon's board of directors.
16:08 EDTLXRXLexicon reports Q1 EPS (4c), consensus (4c)
Reports Q1 revenue $1.79M, consensus $1.1M.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use